Norway's OTC Market In 2018: Sales Remain Stable As GSK Consolidates Its Leading Position
Executive Summary
Sales of non-prescription medicines in Norway edged up by less than 1% in 2018, as GSK remained the leading player on the market and its Otrivin respiratory line maintained its position as the country's best-selling OTC brand.
You may also be interested in...
Karo Grabs Sweden’s Trimb To Grow Presence In Nordics
Karo’s new private-equity owners have flexed their muscles to snap up Sweden’s Trimb in a move which will expand the company’s reach in the Nordics and beyond.
People Round-Up: Appointments At Afipa, J&J, Stada, WSMI, And Karo
J&J Consumer has a new chairman, Stada UK gets a permanent head, and Karo names its next CEO. On the association front, France's Afipa and the WSMI elect new leaders.
Sweden Seeks To Tackle Opioid Overdose Deaths With Naloxone Rx-To-OTC Switch
Opioid antagonist naloxone will soon be available without prescription in Sweden following a successful Rx-to-OTC application from Norway's DNE Pharma.